arrow
M

Mayte Pérez-Olmeda

centro nacional de microbiología
H指数:31
被引数:5,419

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated human seroprevalence study and entomological surveillance of West Nile virus in Cádiz, Spain

西葡加的斯地区西尼罗病毒的血清流行病学调查与媒介监测综合研究

2026-10-210
OAAI
Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV
2026-01-210
OAAI
Blood donor West Nile virus screening identifies three autochthonous Usutu virus infections in Spain

献血者西尼罗河病毒筛查在西班牙发现了三例本土乌斯图病毒感染。

2025-11-040
OAAI
Correction: Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis

更正:SARS-CoV-2疫苗接种在慢性淋巴细胞白血病个体中的免疫应答动力学:一项描述性分析

2025-09-200
OAAI
Design and Implementation of a Nationwide Population-Based Longitudinal Survey of SARS-CoV-2 Infection in Spain: The ENE-COVID Study
2023-05-013
OA
Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2 Vaccination

1273 mRNA SARS-CoV-2疫苗接种后,长期血液透析患者有效的细胞和体液免疫反应的维持

2023-04-113
OAAI
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
2023-03-263
OAAI
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

用两剂实验性新型冠状病毒肺炎疫苗 (CVnCOV) 预防接种,然后用标准mRNA疫苗 (BNT162b2) 进行第三至第四次注射后的免疫反应和反应原性: RescueVacs多中心队列研究

2022-09-015
OAAI
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
2022-08-014
OAAI
Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19
2022-05-165
OAAI
Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection
2022-04-114
OAAI
Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain
2022-04-016
OAAI
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
2022-03-236
OAAI
ENE-COVID nationwide serosurvey served to characterize asymptomatic infections and to develop a symptom-based risk score to predict COVID-19
2021-11-019
OAAI
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
2021-10-1594
OA